Primary filtering device for treating volatile organic compounds and operation method

This patented technology describes an improved filtering apparatus used during chemical vapor deposition (CVD) processes. These filters include two main parts: one part consists primarily of activated carbon or other materials made from porous material like charcoal), which acts as a filtration medium while another part contains tiny holes filled with small molecules called solvent. When these components come into contact with each others they work together to remove impurities such as harmful gases from the air being processed. Overall this design improves the quality of indoor environments produced when manufacturing coatings without causing environmental concerns due to high levels of particulate pollution.

Technological Problem addressed in this patents relates to environmental concerns caused by industrial wastewater containing various substances that may contaminate indoor environments and pose potential hazards to human bodies due to their negative effects upon both humans' sense organs like olfactory function and smell perception. Existing methods involve filters made from petroleum based materials, including activated carbon powders, silica gel, barium sulfide, calcium magnesium aluminum oxides, zinc octoysilicate, tungsten hexadecachloromale acid, polytetrafluoroethylenegligand, cyclohexadienal dimmer, 2-(dimethoxymethanesulfonic), 3 -(2'-cyano-3 '-propyn-1', 1-, 4-)-2-butyrroloxydiminoacetic acid, pivalence scintillator crystal, nitrified vinyl chains, ammonia, trimethylethanonamine, benzoquinones, naptha, paraffin wax, polyvinyl formal resins, aliphatic monocaprolactonitrile, diisobutyl phosphorylcholine, triphenols, carboxylic acids, alkali metal salts, synthetic rubbers, plasticizers, lubricants, surfactant liquors, pesticidal agents, and other ingredients involved in paint industries. These compositions contain volatiles and impurities that contribute to poor performance of pain relief mechanisms found within coatings manufacturing processes. Therefore, there exists a technical problem associated with current solutions involving traditional techniques for treating volatile Organ Leutropes (Volatile Nims).